V8261

(±)-Vigabatrin

• Synonym(e): (R,S)-4-Amino-5-hexenoic acid, (±)-γ-Vinyl-GABA, (±)-4-Aminohexenoic acid
• Empirische Formel (Hill-System): C₆H₁₁NO₂
• CAS-Nummer: 68506-86-5
• Molekulargewicht: 129.16
• EG-Nummer: 270-929-6
• MDL-Nummer: MFCD00274577
• UNSPSC-Code: 12352200
• PubChem Substanz-ID: 24278202
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 200
• Ersteller: Lundbeck
• SMILES String: NC(CCC(O)=O)C=C
• InChI: 1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)
• InChIKey: PJDFLNIOAUIZSL-UHFFFAOYSA-N
• Angaben zum Gen: human ... ABAT(18) , GABBR1(2550) , GABBR2(9568) , GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562)

Beschreibung

Biochem./physiol. Wirkung

Irreversible GABA transaminase inhibitor. Increases intracellular concentration of GABA in nerve endings; possesses antiepileptic activity.

Leistungsmerkmale und Vorteile

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound is featured on the GABA Transporters, GABAA Receptors and Glutamate/GABA Synthesis and Metabolism pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Lundbeck. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Piktogramme: GHS08
• Signalwort: Danger
• H-Sätze: H372
• P-Sätze: P260 - P264 - P270 - P314 - P501
• Gefahreneinstufungen: STOT RE 1
• Zielorgane: Eyes,Central nervous system
• Lagerklassenschlüssel: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• WGK: WGK 1
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable
• Persönliche Schutzausrüstung: dust mask type N95 (US), Eyeshields, Gloves